PEDIATRIC EYE DISEASE INVESTIGATOR GROUP: CHAIR'S OFFICE

描述（由申请人提供）：此网络主席办公室应用程序是3个并行应用程序之一，为儿童眼病研究小组（PEDIG）提供五年的资金扩展。自1997年成立以来，PEDIG已经进行了4项斜视方案、19项弱视方案、3项鼻泪管阻塞方案、2项近视/远视方案和几项试点研究。到本申请所要求的资金开始时，预计在当前周期内将启动3项新方案：一项评估会聚不足治疗的随机试验，一项比较肉毒杆菌毒素与内斜视切口手术的随机试验，以及一项评估青少年特发性关节炎儿童葡萄膜炎发病率的临床疾病登记研究。尽管取得了这些成就，许多重要的问题和争议仍然存在于儿童眼科护理和斜视。PEDIG已经开发或将开发临床试验来解决其中的许多问题。其中包括：（1）尽管进行了最大程度的弱视治疗，但仍有视力缺陷的儿童的治疗策略，（2）为幼儿远视处方眼镜与不处方眼镜的效果，（3）间歇性外斜视的最佳手术和非手术治疗，（4）白内障手术后并发症的风险因素，（5）最佳治疗 用于收敛不足。PEDIG下一个五年供资期的具体目标是：（1）完成在资助期开始时预计正在进行的7项方案，（2）启动10项新方案，用于治疗目前管理层没有证明合理性的常见儿科眼部疾病，（3）通过吸引新的研究中心和研究者的参与，并鼓励年轻研究者的参与，继续扩大PEDIG网络，（4）继续教育儿科眼科医生，（5）培训儿科眼科医生和儿科验光师成为临床试验和临床研究的领导者;（6）开发进行未来弱视和斜视试验所需的新方法和结果测量。

DESCRIPTION (provided by applicant): This Network Chair's Office application is one of 3 parallel applications for a five-year extension of funding for the Pediatric Eye Disease Investigator Group (PEDIG). Since its inception in 1997, PEDIG has conducted 4 protocols in strabismus, 19 protocols in amblyopia, 3 protocols in nasolacrimal duct obstruction, 2 protocols in myopia/hyperopia, and several pilot studies. By the time the funding requested in this application would begin, it is expected that 3 new protocols will have started in the current cycle a randomized trial to evaluate treatment for convergence insufficiency, a randomized trial to compare botulinum toxin with incisional surgery for esotropia, and a clinical disease registry to evaluate uveitis incidence in children with juvenile idiopathic arthritis. Despite these accomplishments, many important questions and controversies remain in pediatric eye care and strabismus. PEDIG has developed, or will be developing, clinical trials to address many of these questions. These include: (1) treatment strategies for children with a visual deficit despite maximal amblyopia treatment, (2) the effect of prescribing versus not prescribing spectacles for hyperopia in young children, (3) the best surgical and non-surgical treatments for intermittent exotropia, (4) risk factors for complications after cataract surgery, and (5) the optimal treatment for convergence insufficiency. Specific aims for the next 5-year funding period for PEDIG are to: (1) complete the 7 protocols that are expected to be in progress at the time the funding period begins, (2) initiate 10 new protocols in common pediatric eye disorders where the current management does not have a proven rationale, (3) continue to expand the PEDIG network by soliciting the participation of new sites and investigators and encouraging the involvement of young investigators, (4) continue to educate pediatric ophthalmologists, pediatric optometrists, and clinical research coordinators on the principles of clinical trials and good clinical research practices, (5) train pediatric ophthalmologists and pediatric optometrists to be leaders in clinica trials and clinical research, and (6) develop new methods and outcome measures needed to conduct future amblyopia and strabismus trials.